The development of artificial neural networks to predict virological response to combination HIV therapy

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 15-24

  Larder, Brendan ^a   Wang, Dechao ^a   Revell, Andrew ^a   Montaner, Julio ^b   Harrigan, Richard ^b   De Wolf, Frank ^c   Lange, Joep ^d   Wegner, Scott ^e   Ruiz, Lidia ^f   Pérez Elías, María Jésus ^g   Emery, Sean ^h   Gatell, Jose ⁱ   Monforte, Antonella D'Arminio ^j   Torti, Carlo ^k   Zazzi, Maurizio ^l   Lane, Clifford ^m  

^a The HIV Resistance Response Database Initiative (RDI)   (United Kingdom)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c STICHTING HIV MONITORING   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f IrsiCaixa Foundation   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l UNIVERSITY OF SIENA   (Italy)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOINFORMATICS; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; VIROTHERAPY; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; DRUG RESISTANCE, VIRAL; EUROPE; GENOTYPE; HIV INFECTIONS; HUMANS; MEDICAL RECORDS; NEURAL NETWORKS (COMPUTER); PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD;

EID: 33847375483     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362:2002-2011.
2. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
3. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (2006). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: Department of Health and Human Services.
4. Vandamme AM, Sönnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 6:829-848
5. Aceti A, Carosi G. Genotypic resistance tests in the management of the HIV-infected patient at virological failure. Scand J Infect Dis Suppl 2003; 35 Suppl 106:61-66.
6. Moroni M, Monforte AD. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure. Scand J Infect Dis Suppl 2003; 35 Suppl 106:79-81.
7. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18:1137-1146.
8. Ormaasen V, Sandvik L, Asjo B, Holberg-Petersen M, Gaarder P, Bruun J. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. HIV Med 2004; 5:400-406.
9. Wang K, Jenwitheesuk E, Samudrala R, Mittler JE. Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance. Antivir Ther 2004; 9:343-352.
10. Sturmer M, Doerr HW, Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion? Curr Drug Targets Infect Disord 2003; 3:373-382.
11. Schapiro JM, De Luca A, Harrigan PR, et al. Resistance assay interpretation systems vary widely in method and approach. Antivir Ther 2001; 6 Suppl 1:131.
12. Gallego O, Martin-Carbonero L, Aguero J, de Mendoza C, Corral A, Soriano V. Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. J Virol Methods 2004; 121:115-118.
13. Beerenwinkel N, Daumer M, Oette M, et al. Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res 2003; 31:3850-3855.
14. Shafer RW, Gonzales MJ, Brun-Vezinet F. Online comparison of HIV-1 drug resistance algorithms identifies rates and causes of discordant interpretations. Antivir Ther 2001; 6 Suppl 1:101.
15. Torti C, Quiros-Roldan E, Keulen W, et al. for the GenPherex Group of the MaSTeR Cohort. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis 2003; 188:194-201
16. Sturmer M, Doerr HW, Staszewski S, Preiser W. Comparison of nine resistance interpretation systems for HIV-1 genotyping. Antivir Ther 2003; 8:239-244.
17. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 15:1934-1943.
18. Beerenwinkel N, Sing T, Lengauer T, et al. Computational models for the design of effective therapies against drug resistant HIV strains. Bioinformatics 2005; 21: 3943-3950.
19. Wang D, Larder B. Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 2003; 188:653-660.
20. Beerenwinkel N, Schmidt B, Walter H, et al. Diversity and complexity of HIV-1 drug restiance: a bioinformatics approach to predicting pnenotype form genotype. Proc Natl Acad Sci 2002; 99:8271-8276.
21. Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antivir Ther 2000; 5 Suppl 3:49.
22. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
23. Bachelor L, Winter B, Nauwelauers D, et al. Estimation of phenotypic clinical cut-offs for VirtualPhenotype through meta analyses of clinical trial and cohort data. Antivir Ther 2004; 9: S154.
24. Swanstrom R, Bosch R, Katzenstein, D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004; 190:886-893.
25. DiRienzo G and DeGruttola V. Collaborative HIV resistance-response database: sample size for detection of relationships between HIV-1 genotype and HIV-1 RNA response using a non-parametric approach. Antivir Ther 2002; 7:S71.
26. Larder, BA, DeGruttola, V, Hammer, et al. The international HIV resistance response database initiative: a new global collaborative approach to relating viral genotype treatment to clinical outcome. Antivir Ther 2002; 7:S84.
27. Tham CK, Heng CK, Chin WC. Predicting risk of coronary artery disease from DNA microarray-based genotyping using neural networks and other statistical analysis tool. J Bioinform Comput Biol 2003; 1:521-539.
28. Heckerling PS, Gerber BS, Tape TG, Wigton RS. Use of genetic algorithms for neural networks to predict community-acquired pneumonia. Artif Intell Med 2004; 30:71-84.
29. Pociot F, Karlsen AE, Pedersen CB, Aalund M, Nerup J, European Consortium for IDDM Genome Studies. Novel analytical methods applied to type 1 diabetes genome-scan data. Am J Hum Genet 2004; 74:647-660.
30. Agatonovic-Kustrin S, Beresford R. Basic concepts of artificial neural network (ANN) modelling and its application in pharmaceutical research. J Pharm Biomed Anal 2000; 22:717-727.
31. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
32. Wang D, Larder B, Revell A, Harrigan R, Montaner JA neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antivir Ther 2003; 8:S112.
33. Larder BA, Wang D, Revell A, Lane C. Neural network model identified potentially effective drug combinations for patients failing salvage therapy. The 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, France, 13-16 July 2003. Poster LB39.
34. Larder BA, Wang D, Revell A, Harrigan R, Montaner J, Lane C. Accuracy of neural network nodels in predicting HIV treatment response from genotype may depend on diversity as well as size of datasets. The 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004. Poster 697.
35. Revell A, Larder BA, Wang D, et al. Global neural network models are superior to single clinic models as general quantitative predictors of virological treatment response. 3rd IAS Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Poster WePe12.6C04.
36. Mellors J, Palmer S, Nissley D, et al. for the ACTG 398 Study Team. Low frequency of non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes of NNRTI mutations. Antivir Ther 2003; 8:S150.
37. Larder B, Wang D, Revell A, Harrigan R, Montaner J, Lane C. Previous drug exposure data significantly increase the accuracy of artificial neural networks in predicting virological response to combination therapy. Antivir Ther 2004; 9:S123.
38. Larder B A, Wang D, Revell A, et al. Treatment history, CD4 count but not previous genotype improves the accuracy of predicting virological response to HIV therapy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, 16-19 December 2005. Poster H-1051.
39. Wegner S, Larder BA, Wang D, et al. Global neural network models are superior to single clinic models as general quantitative predictors of virological treatment response. Antivir Ther 2005; 10:S58.
40. Hales G, Birch C, Crowe S, et al. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: The CREST study PLoS Clin Trials 2006; 1:e18.
41. Geman S, Bienenstock E, Doursat R. Neural networks and the bias/variance dilemma. Neural Comput 1992; 4:1-58.